메뉴 건너뛰기




Volumn 2, Issue 1, 2013, Pages 11-24

Effects of trastuzumab emtansine (T-DM1) on Qt interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer

Author keywords

Breast cancer; Human epidermal growth factor receptor 2 positive; Pertuzumab; QT interval; T DM1; Trastuzumab emtansine

Indexed keywords

AMLODIPINE BESYLATE; ANTHRACYCLINE; CAPECITABINE; CARVEDILOL; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LAPATINIB; METOPROLOL; METOPROLOL SUCCINATE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VENLAFAXINE;

EID: 84891966611     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.9     Document Type: Article
Times cited : (32)

References (37)
  • 1
    • 38949192547 scopus 로고    scopus 로고
    • Targeted cancer therapy: conferring specificity to cytotoxic drugs
    • Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
    • (2008) Acc Chem Res. , vol.41 , pp. 98-107
    • Chari, R.V.1
  • 2
    • 56449129810 scopus 로고    scopus 로고
    • Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
    • Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68: 9280-9290.
    • (2008) Cancer Res. , vol.68 , pp. 9280-9290
    • Lewis Phillips, G.D.1    Li, G.2    Dugger, D.L.3
  • 3
    • 77954031486 scopus 로고    scopus 로고
    • Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
    • Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698-2704.
    • (2010) J Clin Oncol. , vol.28 , pp. 2698-2704
    • Krop, I.E.1    Beeram, M.2    Modi, S.3
  • 4
    • 79952092706 scopus 로고    scopus 로고
    • Phase II study of the antibody drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy
    • Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy. J Clin Oncol. 2011;29: 398-405.
    • (2011) J Clin Oncol. , vol.29 , pp. 398-405
    • Burris, H.A.1    Rugo, H.S.2    Vukelja, S.J.3
  • 5
    • 79959700509 scopus 로고    scopus 로고
    • Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
    • Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347-356.
    • (2011) Breast Cancer Res Treat. , vol.128 , pp. 347-356
    • Junttila, T.T.1    Li, G.2    Parsons, K.3    Phillips, G.L.4    Sliwkowski, M.X.5
  • 6
    • 84863688392 scopus 로고    scopus 로고
    • A phase II study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    • Krop I, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30:3234-3241.
    • (2012) J Clin Oncol. , vol.30 , pp. 3234-3241
    • Krop, I.1    LoRusso, P.2    Miller, K.D.3
  • 7
    • 84874822884 scopus 로고    scopus 로고
    • A phase 2 randomized study of trastuzumab emtansine (T-DM1) versus trastuzumab docetaxel in patients with HER2-positive metastatic breast cancer
    • [in press]
    • Hurvitz SA, Dirix L, Kocsis J, et al. A phase 2 randomized study of trastuzumab emtansine (T-DM1) versus trastuzumab docetaxel in patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2013; [in press].
    • (2013) J Clin Oncol.
    • Hurvitz, S.A.1    Dirix, L.2    Kocsis, J.3
  • 8
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 2012;367:1783-1791.
    • (2012) New Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3
  • 9
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
    • (2001) N Engl J Med. , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 10
    • 80052728749 scopus 로고    scopus 로고
    • Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31
    • Perez EA, Romond EH, Suman VJ, et al. Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373.
    • (2011) J Clin Oncol. , vol.29 , pp. 3366-3373
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3
  • 11
  • 12
    • 84892489044 scopus 로고    scopus 로고
    • U.S,Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). International conference on harmonisation guidance for industry: E14 clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs,Published October 2005. Accessed February 15, 2012
    • U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). International conference on harmonisation guidance for industry: E14 clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM129357.pdf. Published October 2005. Accessed February 15, 2012.
    • Department of Health and Human Services Food and Drug Administration
  • 13
    • 14544268139 scopus 로고    scopus 로고
    • QT prolongation through hERG K() channel blockade: current knowledge and strategies for the early prediction during drug development
    • Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K() channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev. 2005;25:133-166.
    • (2005) Med Res Rev. , vol.25 , pp. 133-166
    • Recanatini, M.1    Poluzzi, E.2    Masetti, M.3    Cavalli, A.4    De Ponti, F.5
  • 14
    • 30344462409 scopus 로고    scopus 로고
    • Prolonged QTc interval and risk of sudden cardiac death in a population of older adults
    • Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367.
    • (2006) J Am Coll Cardiol. , vol.47 , pp. 362-367
    • Straus, S.M.1    Kors, J.A.2    De Bruin, M.L.3
  • 16
    • 35348851892 scopus 로고    scopus 로고
    • The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients
    • Yavas O, Yazici M, Eren O, Oyan B. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly. 2007;137:556-558.
    • (2007) Swiss Med Wkly. , vol.137 , pp. 556-558
    • Yavas, O.1    Yazici, M.2    Eren, O.3    Oyan, B.4
  • 17
    • 77949808844 scopus 로고    scopus 로고
    • A simple approach discriminating cardio-safe drugs from toxic ones
    • Falah M, Nassar T, Rayan A. A simple approach discriminating cardio-safe drugs from toxic ones. Bioinformation. 2009;3:389-393.
    • (2009) Bioinformation. , vol.3 , pp. 389-393
    • Falah, M.1    Nassar, T.2    Rayan, A.3
  • 18
    • 77957830531 scopus 로고    scopus 로고
    • Electrocardiographic assessment for therapeutic proteins-scientific discussion
    • Rodriguez I, Erdman A, Padhi D, et al. Electrocardiographic assessment for therapeutic proteins-scientific discussion. Am Heart J. 2010;160:627-634.
    • (2010) Am Heart J. , vol.160 , pp. 627-634
    • Rodriguez, I.1    Erdman, A.2    Padhi, D.3
  • 19
    • 2442562493 scopus 로고    scopus 로고
    • Drugs, hERG and sudden death
    • Brown AM. Drugs, hERG and sudden death. Cell Calcium. 2004;35:543-547.
    • (2004) Cell Calcium. , vol.35 , pp. 543-547
    • Brown, A.M.1
  • 20
    • 44949175102 scopus 로고    scopus 로고
    • Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents
    • Sarapa N, Britto MR. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf. 2008;7:305-318.
    • (2008) Expert Opin Drug Saf. , vol.7 , pp. 305-318
    • Sarapa, N.1    Britto, M.R.2
  • 22
    • 33644600485 scopus 로고    scopus 로고
    • Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
    • Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55:717-727.
    • (2006) Cancer Immunol Immunother. , vol.55 , pp. 717-727
    • Adams, C.W.1    Allison, D.E.2    Flagella, K.3
  • 23
    • 84892489026 scopus 로고    scopus 로고
    • Presented at: American Association for Cancer Research 101st Annual Meeting; April 17-21, 2010
    • Washington,DC.Abstract 5607
    • Fields CT, Crocker LM, Sliwkowski MX, et al. Presented at: American Association for Cancer Research 101st Annual Meeting; April 17-21, 2010; Washington,DC.Abstract 5607.
    • Fields, C.T.1    Crocker, L.M.2    Sliwkowski, M.X.3
  • 24
    • 84892488879 scopus 로고    scopus 로고
    • Drugs that prolong the QT interval and/or induce torsades de pointes
    • Accessed February 15, 2012
    • Arizona Center for Education and Research on Therapeutics. Drugs that prolong the QT interval and/or induce torsades de pointes. http://www.azcert.org/medical-pros/drug-lists/ browse-drug-list.cfm. Accessed February 15, 2012.
    • Arizona Center for Education and Research on Therapeutics.
  • 25
    • 84980098899 scopus 로고
    • The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease
    • Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica. 1920;53:469-486.
    • (1920) Acta Medica Scandinavica. , vol.53 , pp. 469-486
    • Fridericia, L.S.1
  • 26
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P, Arbuck SG, Eisenhaur EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
    • (2000) J Natl Cancer Inst. , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhaur, E.A.3
  • 27
    • 84860307997 scopus 로고    scopus 로고
    • Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
    • Gupta M, LoRusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012;52:691-703.
    • (2012) J Clin Pharmacol. , vol.52 , pp. 691-703
    • Gupta, M.1    LoRusso, P.M.2    Wang, B.3
  • 28
    • 78650516508 scopus 로고    scopus 로고
    • Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposureresponse analysis: case study of a thorough QT study of asenapine
    • Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposureresponse analysis: case study of a thorough QT study of asenapine. Clin Pharmacol Ther. 2011;89:75-80.
    • (2011) Clin Pharmacol Ther. , vol.89 , pp. 75-80
    • Chapel, S.1    Hutmacher, M.M.2    Bockbrader, H.3    de Greef, R.4    Lalonde, R.L.5
  • 29
    • 37349079996 scopus 로고    scopus 로고
    • Concentration- QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review
    • Garnett CE, Beasley N, Bhattaram VA, et al. Concentration- QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48:13-18.
    • (2008) J Clin Pharmacol. , vol.48 , pp. 13-18
    • Garnett, C.E.1    Beasley, N.2    Bhattaram, V.A.3
  • 31
    • 84892488993 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen
    • December 8-12, 2010; San Antonio, TX. Abstract P3-14-22
    • Lu D, Krop IE, Modi S, et al. Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-22.
    • Presented at: San Antonio Breast Cancer Symposium
    • Lu, D.1    Krop, I.E.2    Modi, S.3
  • 32
    • 84865748679 scopus 로고    scopus 로고
    • Drug interaction potential of trastuzumab emtansine combined with pertuzumab in patients with HER2-positive metastatic breast cancer
    • Lu D, Burris HA III, Wang B, et al. Drug interaction potential of trastuzumab emtansine combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Current Drug Metab. 2012;13:911-922.
    • (2012) Current Drug Metab. , vol.13 , pp. 911-922
    • Lu, D.1    Burris, H.A.2    Wang, B.3
  • 34
    • 84862228236 scopus 로고    scopus 로고
    • Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2- positive cancer
    • Girish S, Gupta M, Wang B, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2- positive cancer. Cancer Chemother Pharmacol. 2012;69: 1229-1240.
    • (2012) Cancer Chemother Pharmacol. , vol.69 , pp. 1229-1240
    • Girish, S.1    Gupta, M.2    Wang, B.3
  • 35
    • 64349093768 scopus 로고    scopus 로고
    • Assessing proarrhythmic potential of drugs when optimal studies are infeasible
    • 836.e1,doi: 10.1016/j.ahj.2009.02.020
    • Rock EP, Finkle J, Fingert HJ, et al. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827-836, 836.e1. doi: 10.1016/j.ahj.2009.02.020.
    • (2009) Am Heart J. , vol.157 , pp. 827-836
    • Rock, E.P.1    Finkle, J.2    Fingert, H.J.3
  • 36
    • 40249094483 scopus 로고    scopus 로고
    • Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
    • Curigliano G, Spitaleri G, Fingert HJ, et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer. 2008;44:494-500.
    • (2008) Eur J Cancer. , vol.44 , pp. 494-500
    • Curigliano, G.1    Spitaleri, G.2    Fingert, H.J.3
  • 37
    • 84892489003 scopus 로고    scopus 로고
    • A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results
    • Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-01
    • Dieras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-01.
    • Dieras, V.1    Harbeck, N.2    Albain, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.